Literature DB >> 12534941

IL-4 responsive CD4+ T cells specific for myelin basic protein: IL-2 confers a prolonged postactivation refractory phase.

Mark D Mannie1, Dana J Fraser, Thomas J McConnell.   

Abstract

This study compared myelin basic protein-specific T cells from Lewis rats that were derived in the presence of either rat IL-4 or IL-2. Interleukin-4 was a maintenance factor that enabled derivation of long-term T cell lines. When activated, IL-4 dependent lines were lacking in IL-2 production capacity but maintained high levels of responsiveness to IL-2 and recognized IL-2 as a dominant growth factor. Activated IL-4 dependent T cells rapidly reverted to a quiescent phenotype in the presence of IL-4 and rapidly regained myelin basic protein reactivity. In contrast, activated IL-2 dependent T cells that were propagated in IL-2 had a more persistent blastogenic phenotype and a prolonged refractory phase. Interleukin-4 dependent lines that were propagated in IL-2 up-regulated the capacity to produce IL-2 and also acquired prolonged postactivation refractoriness. Thus, IL-2 was a dominant growth factor that conferred prolonged activation-dependent non-responsiveness. The coupling of dominant growth factor activity with prolonged postactivation refractoriness may be associated with the requisite role of IL-2 in homeostatic self-tolerance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12534941     DOI: 10.1046/j.1440-1711.2003.01131.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  8 in total

Review 1.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

2.  Deciphering the Finger Prints of Brain Cancer Glioblastoma Multiforme from Four Different Patients by Using Near Infrared Raman Spectroscopy.

Authors:  Hirendra Nath Banerjee; Arnold Banerji; Arunendra Nath Banerjee; Eilena Riddick; Jenae Petis; Shavonda Evans; Megha Patel; Carl Parson; Valerie Smith; E Gwebu; Sarah Voisin
Journal:  J Cancer Sci Ther       Date:  2015-02-03

3.  Deciphering the finger prints of brain cancer astrocytoma in comparison to astrocytes by using near infrared Raman spectroscopy.

Authors:  Hirendra Nath Banerjee; L Zhang
Journal:  Mol Cell Biochem       Date:  2006-08-22       Impact factor: 3.396

4.  A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC.

Authors:  J Lori Blanchfield; Mark D Mannie
Journal:  J Leukoc Biol       Date:  2010-03       Impact factor: 4.962

5.  Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE).

Authors:  Derek J Abbott; J Lori Blanchfield; David A Martinson; Sean C Russell; Najla Taslim; Alan D Curtis; Mark D Mannie
Journal:  BMC Immunol       Date:  2011-12-30       Impact factor: 3.615

6.  Partial CD25 Antagonism Enables Dominance of Antigen-Inducible CD25high FOXP3+ Regulatory T Cells As a Basis for a Regulatory T Cell-Based Adoptive Immunotherapy.

Authors:  Daniel S Wilkinson; Debjani Ghosh; Rebecca A Nickle; Cody D Moorman; Mark D Mannie
Journal:  Front Immunol       Date:  2017-12-14       Impact factor: 7.561

7.  A GM-CSF-neuroantigen tolerogenic vaccine elicits inefficient antigen recognition events below the CD40L triggering threshold to expand CD4+ CD25+ FOXP3+ Tregs that inhibit experimental autoimmune encephalomyelitis (EAE).

Authors:  Cody D Moorman; Alexander G Bastian; Kayla B DeOca; Mark D Mannie
Journal:  J Neuroinflammation       Date:  2020-06-10       Impact factor: 8.322

8.  A Novel Catecholopyrimidine Based Small Molecule PDE4B Inhibitor Suppresses Inflammatory Cytokines in Atopic Mice.

Authors:  Baskaran Purushothaman; Parthasarathy Arumugam; Joon Myong Song
Journal:  Front Pharmacol       Date:  2018-05-11       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.